SCHEDULE: Ikarian Capital Discloses 4.8% Stake in Relmada
Schedule 13G Filing
Ikarian Capital and Neil Shahrestani have reported a 4.8% passive beneficial ownership stake in Relmada Therapeutics, Inc. as of September 30, 2025.
Summary
- Ikarian Capital, LLC and Neil Shahrestani (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The Reporting Persons beneficially own 3,543,359 shares of common stock of Relmada Therapeutics, Inc.
- This ownership represents 4.8% of the outstanding common stock of Relmada Therapeutics, Inc.
- The percentage is based on 73,333,622 shares of common stock outstanding as of November 10, 2025, as reported in the Issuer's Form 10-Q filed on November 13, 2025.
- Ikarian Capital, LLC is a Delaware limited liability company and an investment adviser.
- Neil Shahrestani is a U.S. citizen and indirectly controls Ikarian Capital, LLC.
- The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separate managed accounts.
- The Reporting Persons have shared voting and shared dispositive power over all 3,543,359 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, with no positive or negative implications for the company's operational or financial performance.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or operations, as it is solely a disclosure of beneficial ownership.
Industry Context
This filing is a standard disclosure of a passive investment stake by an investment adviser and its principal in a publicly traded company. It does not provide insights into broader industry trends or competitive landscape, but rather reflects an investment decision by a specific fund manager.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive investor's stake, which could be viewed positively as a vote of confidence, but does not imply active engagement or control changes.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires filing of this statement |
| 2025-11-10 | Date as of which 73,333,622 shares of Common Stock were outstanding, as disclosed in the Issuer's Form 10-Q |
| 2025-11-13 | Date Relmada Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2025 |
| 2025-11-14 | Date of signing and filing of this Schedule 13G statement |
Keywords
Relmada Therapeutics, Ikarian Capital, Neil Shahrestani, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.